XM does not provide services to residents of the United States of America.
D
D

DaVita

News

FMC specifies 2024 guidance as it tops Q3 core profit forecast

UPDATE 2-FMC slightly raises 2024 guidance as it tops Q3 core profit forecast Adds CEO quotes in paragraphs 3, 9, shares in paragraph 6, peer performance in paragraph 7 By Bartosz Dabrowski and Patricia Weiss Nov 5 (Reuters) - Dialysis specialist Fresenius Medical Care FMEG.DE slightly raised the lower end of its 2024 operating profit forecast range on Tuesady after posting quarterly earnings above expectations, helped by cost savings and as its U.S.
F
D

U.S. STOCKS Zimmer Biomet, Shake Shack, Microsoft

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes advanced on Wednesday, with the tech-heavy Nasdaq rising to a record high, as investors assessed corporate earnings as well as crucial data showing the economy maintained a steady pace of growth in the third quarter.
A
A
B
C
C
D
E
G
M
M
N
Q
Q
V
A
K
S
U
U
G
W
Z
D
F
O

DaVita Inc reports results for the quarter ended in January 1 - Earnings Summary

DaVita Inc reports results for the quarter ended in January 1 - Earnings Summary DaVita Inc DVA.N reported quarterly adjusted earnings of $2.50​​ per share for the quarter ended January 1, lower than the same quarter last year, when the company reported EPS of $2.62. The mean expectation of seven analysts for the quarter was for earnings of $2.73 per share.
D

Dialysis firm DaVita misses third-quarter profit estimates on higher costs

UPDATE 3-Dialysis firm DaVita misses third-quarter profit estimates on higher costs Updates shares, adds details from conference call in paragraphs 3-7 By Sneha S K Oct 29 (Reuters) - Dialysis firm DaVita DVA.N reported third -quarter profit below Wall Street estimates on Tuesday due to increased labor costs and other expenses tied to patient care, sending its shares down 5 .3 % after the bell.
D

DaVita misses third-quarter profit estimates on higher costs

DaVita misses third-quarter profit estimates on higher costs Oct 29 (Reuters) - DaVita DVA.N reported third-quarter profit that missed Wall Street estimates on Tuesday, hurt by high patient care costs . On an adjusted basis, it reported third-quarter profit of $2.59 per share, below analysts' estimate of $2.73 per share. Reporting by Sneha S K; Edi
D

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.